Jotham W. Coe

Varenicline:  An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation

Jotham W. Coe, Paige R. Brooks, Michael G. Vetelino et al. · Journal of Medicinal Chemistry · 2005 · 933 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Delineating the role of cooperativity in the design of potent PROTACs for BTK

Adelajda Zorba, Chuong Nguyen, Yingrong Xu et al. · Proceedings of the National Academy of Sciences · 2018 · 423 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +15

Direct activation of relatively unstrained carbon–carbon bonds in homogeneous systems

Alpay Dermenci, Jotham W. Coe, Guangbin Dong · Organic Chemistry Frontiers · 2014 · 262 citations · Full text

Natural Sciences, Chemistry, Catalysis +14

METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRO

R. Scott Obach, Anne E. Reed‐Hagen, Suzanne S Krueger et al. · Drug Metabolism and Disposition · 2005 · 201 citations

Medicine, Pharmacokinetics, Pharmacology +17

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2<i>S</i>,5<i>R</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans

Atli Thorarensen, Martin E. Dowty, Mary Ellen Banker et al. · Journal of Medicinal Chemistry · 2017 · 165 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14